Authors' response to Hermann <i>et al</i>. Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from RCTs

Koenraad Blot, Martin C. Michel

Open source

DOI
10.1111/j.1365-2125.2012.04180.x
Published
2012-06-11
Container
British Journal of Clinical Pharmacology
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/j.1365-2125.2012.04180.x,
  title = {Authors' response to Hermann <i>et al</i>. Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from RCTs},
  author = {Koenraad Blot and Martin C. Michel},
  year = {2012},
  journal = {British Journal of Clinical Pharmacology},
  doi = {10.1111/j.1365-2125.2012.04180.x},
  url = {https://doi.org/10.1111/j.1365-2125.2012.04180.x}
}

RIS

TY  - JOUR
TI  - Authors' response to Hermann <i>et al</i>. Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from RCTs
AU  - Koenraad Blot
AU  - Martin C. Michel
PY  - 2012
JO  - British Journal of Clinical Pharmacology
DO  - 10.1111/j.1365-2125.2012.04180.x
UR  - https://doi.org/10.1111/j.1365-2125.2012.04180.x
ER  - 

APA

Blot, K., & Michel, M. C. (2012). Authors' response to Hermann <i>et al</i>. Minimum quality criteria are needed in the assessment and communication of unexpected drug safety findings of marketed products from RCTs. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2012.04180.x

Source records